Viking Therapeutics (VKTX) Income from Continuing Operations (2014 - 2026)

Viking Therapeutics has disclosed Income from Continuing Operations across 13 years of filings, most recently posting 158325000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 158325000.0, down 247.17% year-over-year; the trailing twelve-month figure through Mar 2026 was 472358000.0 (down 268.29% YoY), and the FY2025 annual result was 359638000.0, down 227.0% from the prior year.
• Income from Continuing Operations came in at 158325000.0 for Q1 2026 at Viking Therapeutics, roughly flat from 157703000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 15746000.0 in Q3 2022 to a low of 158325000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 24579000.0 (2023), against an average of 46030411.76.
• Across the five-year window, Income from Continuing Operations declined 10.44% in 2023 and tumbled 345.56% in 2025, its largest moves.
• Viking Therapeutics' Income from Continuing Operations stood at 19551000.0 in 2022, then fell by 25.72% to 24579000.0 in 2023, then sank by 44.0% to 35394000.0 in 2024, then tumbled by 345.56% to 157703000.0 in 2025, then decreased by 0.39% to 158325000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 158325000.0 (Q1 2026), 157703000.0 (Q4 2025), and 90789000.0 (Q3 2025), per Business Quant data.